home / stock / evok / evok news

EVOK News and Press, Evoke Pharma Inc. From 11/08/23

Stock Information
Company Name: Evoke Pharma Inc.
Stock Symbol: EVOK
Market: NASDAQ
Website: evokepharma.com
Menu
EVOK EVOK Quote EVOK Short EVOK News EVOK Articles EVOK Message Board
Get EVOK Alerts

News, Short Squeeze, Breakout and More Instantly...
EVOK - Expected earnings - Evoke Pharma Inc.

Evoke Pharma Inc. (EVOK) is expected to report for Q1 2024
EVOK - Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023

SOLANA BEACH, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK) , a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, and EVERSANA, a le...

EVOK - 7 Under-the-Radar Growth Stocks Ready to Make a Splash

2023-10-23 06:30:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If I’m looking to outperform the market over time, I’m usually going to buy growth stocks . While value stocks have a place in any portfolio, growth stocks are the ones that k...

EVOK - Evoke Pharma's Abstract Entitled "Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients" to Be Presented at The American College of Gastroenterology (ACG) 2023 An

SOLANA BEACH, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that its real-world he...
EVOK - Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®

SOLANA BEACH, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that it has b...

EVOK - Evoke Pharma GAAP EPS of -$0.56 beats by $0.17, revenue of $1.13M beats by $0.03M

2023-08-10 10:24:57 ET Evoke Pharma press release ( NASDAQ: EVOK ): Q2 GAAP EPS of -$0.56 beats by $0.17 . Revenue of $1.13M (+145.7% Y/Y) beats by $0.03M . For further details see: Evoke Pharma GAAP EPS of -$0.56 beats by $0.17, revenue of $1.13M beats b...

EVOK - Evoke Pharma Reports Second Quarter 2023 Financial Results

40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare utilization data supporting the benefits of GIMOTI compared to oral metoclopramide at DDW 2023; additional abstracts accepted at future ...
EVOK - Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting

Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide Both organizations recognize and support Gastroparesis Awareness Month through continued support of the International ...

EVOK - Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting

SOLANA BEACH, Calif., and CHICAGO, July 25, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, and EVERSANA!...

EVOK - Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment

SOLANA BEACH, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that it will host a ke...
Previous 10 Next 10